Skip to main
INVA

Innoviva (INVA) Stock Forecast & Price Target

Innoviva (INVA) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 20%
Buy 60%
Hold 0%
Sell 0%
Strong Sell 20%

Bulls say

Innoviva Inc has demonstrated strong financial performance with significant year-over-year sales growth, notably achieving a 33% increase in Giapreza sales from 2023 to 2024 and maintaining over 20% annual sales growth for Xerava since its acquisition. The company's strategic acquisitions have outperformed previous ownership, with annualized run rates for both Giapreza and Xerava nearly doubling since their acquisition in August 2022. Additionally, Giapreza's net sales have risen from $33.4 million in 2021 to $41.3 million in 2023, with projections suggesting further growth to $55 million in 2024, underscoring Innoviva’s effective management and growth potential in its healthcare portfolio.

Bears say

Innoviva Inc is projected to experience a decline in royalty revenues, with sales from GSK forecasted to decrease by an average of 8% year-over-year for Relvar/Breo and 4% for Anoro over the next eight years. Furthermore, the anticipated loss of exclusivity for Giapreza by 2034, combined with concerns about the diminishing efficacy of colistin against multi-drug-resistant strains, presents additional challenges for the company's future revenue streams. Despite potential barriers to generic competition, the company's overall financial outlook remains concerning due to these declining sales expectations and impending patent expirations.

Innoviva (INVA) has been analyzed by 5 analysts, with a consensus rating of Buy. 20% of analysts recommend a Strong Buy, 60% recommend Buy, 0% suggest Holding, 0% advise Selling, and 20% predict a Strong Sell.

This aggregate rating is based on analysts' research of Innoviva and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Innoviva (INVA) Forecast

Analysts have given Innoviva (INVA) a Buy based on their latest research and market trends.

According to 5 analysts, Innoviva (INVA) has a Buy consensus rating as of Dec 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $36.80, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $36.80, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Innoviva (INVA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.